SB 225002

• Supplier: R&D Systems
• Catalog: 2725
• Prices: $189.00, $765.00
• Sizes: 10 mg, 50 mg
• Cas Number: 182498-32-4
• Chemical Name: N-(2-Bromophenyl)-N'-(2-hydroxy-4-nitrophenyl)urea
• Formula: C13H10BrN3O4
• Molecular Weight: 352.14
• Purity: >99%

Product References

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. - Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Gyorffy B, Penninger JM, Popper H, Casanova E. Nat Commun. 2015 Mar 3;6:6285.

Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in - Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in

Lourenco S, Teixeira VH, Kalber T, Jose RJ, Floto RA, Janes SM. J Immunol. 2015 Apr 1;194(7):3463-74.

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic - CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic

Devapatla B, Sharma A, Woo S. PLoS One. 2015 Sep 28;10(9):e0139237.

Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic - Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic

Yuen DA, Zhang Y, Thai K, Spring C, Chan L, Guo X, Advani A, Sivak JM, Gilbert RE. Stem Cells Transl Med. 2012 Dec;1(12):921-6.

Mesenchymal transition and dissemination of cancer cells is driven by - Mesenchymal transition and dissemination of cancer cells is driven by

Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP. PLoS Biol. 2011 Sep;9(9):e1001162.

CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during - CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during

Jang JE, Hod EA, Spitalnik SL, Frenette PS. J Clin Invest. 2011 Apr;121(4):1397-401.